高流量鼻导管氧疗与标准氧疗对免疫抑制合并急性呼吸衰竭患者28天死亡率的影响:HIGH随机临床试验
HIGH随机临床试验在法国32个ICU纳入776例免疫抑制合并急性低氧性呼吸衰竭的成人患者,1:1随机接受持续高流量鼻导管氧疗或标准氧疗。
要点
- 免疫抑制合并急性呼吸衰竭患者中,高流量氧疗未显著降低28天死亡率。
- 高流量氧疗组插管率与标准氧疗组无显著差异(38.7% vs 43.8%)。
- 高流量氧疗可改善6小时PaO2:FIO2并降低呼吸频率,但ICU住院时长等无差异。
核心结论
- 在免疫抑制合并急性呼吸衰竭的危重患者中,与标准氧疗相比,高流量氧疗未显著降低28天死亡率。
研究设计与样本
- HIGH随机临床试验在法国32个ICU纳入776例免疫抑制合并急性低氧性呼吸衰竭的成人患者,按1:1随机分配至高流量氧疗组(n=388)或标准氧疗组(n=388)。
主要发现
- 插管率两组无显著差异:38.7% vs 43.8%,差值-5.1%(95%CI -12.3%至+2.0%)。
- 高流量氧疗组6小时后PaO2:FIO2更高(150 vs 119,差值19.5,95%CI 4.4-34.6),呼吸频率更低(25/min vs 26/min,差值-1.8/min,95%CI -3.2至-0.2)。
- ICU住院时长(8 vs 6天,差值0.6,95%CI -1.0至+2.2)、ICU获得性感染(10.0% vs 10.6%,差值-0.6%,95%CI -4.6至+4.1)、医院住院时长(24 vs 27天,差值-2天,95%CI -7.3至+3.3)及患者舒适度和呼吸困难评分均无显著差异。
临床怎么用
- 对于免疫抑制合并急性呼吸衰竭的危重患者,高流量氧疗可作为氧疗选择之一,但不应期望其显著降低28天死亡率。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: High-flow nasal oxygen therapy is increasingly used for acute hypoxemic respiratory failure (AHRF). OBJECTIVE: To determine whether high-flow oxygen therapy decreases mortality among immunocompromised patients with AHRF compared with standard oxygen therapy. DESIGN, SETTING, AND PARTICIPANTS: The HIGH randomized clinical trial enrolled 776 adult immunocompromised patients with AHRF (Pao2 <60 mm Hg or Spo2 <90% on room air, or tachypnea >30/min or labored breathing or respiratory distress, and need for oxygen ≥6 L/min) at 32 intensive care units (ICUs) in France between May 19, 2016, and December 31, 2017. INTERVENTIONS: Patients were randomized 1:1 to continuous high-flow oxygen therapy (n = 388) or to standard oxygen therapy (n = 388). MAIN OUTCOMES AND MEASURES: The primary outcome was day-28 mortality. Secondary outcomes included intubation and mechanical ventilation by day 28, Pao2:Fio2 ratio over the 3 days after intubation, respiratory rate, ICU and hospital lengths of stay, ICU-acquired infections, and patient comfort and dyspnea. RESULTS: Of 778 randomized patients (median age, 64 [IQR, 54-71] years; 259 [33.3%] women), 776 (99.7%) completed the trial. At randomization, median respiratory rate was 33/min (IQR, 28-39) vs 32 (IQR, 27-38) and Pao2:Fio2 was 136 (IQR, 96-187) vs 128 (IQR, 92-164) in the intervention and control groups, respectively. Median SOFA score was 6 (IQR, 4-8) in both groups. Mortality on day 28 was not significantly different between groups (35.6% vs 36.1%; difference, -0.5% [95% CI, -7.3% to +6.3%]; hazard ratio, 0.98 [95% CI, 0.77 to 1.24]; P = .94). Intubation rate was not significantly different between groups (38.7% vs 43.8%; difference, -5.1% [95% CI, -12.3% to +2.0%]). Compared with controls, patients randomized to high-flow oxygen therapy had a higher Pao2:Fio2 (150 vs 119; difference, 19.5 [95% CI, 4.4 to 34.6]) and lower respiratory rate after 6 hours (25/min vs 26/min; difference, -1.8/min [95% CI, -3.2 to -0.2]). No significant difference was observed in ICU length of stay (8 vs 6 days; difference, 0.6 [95% CI, -1.0 to +2.2]), ICU-acquired infections (10.0% vs 10.6%; difference, -0.6% [95% CI, -4.6 to +4.1]), hospital length of stay (24 vs 27 days; difference, -2 days [95% CI, -7.3 to +3.3]), or patient comfort and dyspnea scores. CONCLUSIONS AND RELEVANCE: Among critically ill immunocompromised patients with acute respiratory failure, high-flow oxygen therapy did not significantly decrease day-28 mortality compared with standard oxygen therapy. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT02739451.
引用
- Azoulay E, Lemiale V, Mokart D, et al. Effect of High-Flow Nasal Oxygen vs Standard Oxygen on 28-Day Mortality in Immunocompromised Patients With Acute Respiratory Failure: The HIGH Randomized Clinical Trial. JAMA. 2018. PMID: 30357270. doi:10.1001/jama.2018.14282
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。